Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Amicus Therapeutics (FOLD) Secures $400 Million Non-Dilutive Debt Financing
-
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
-
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
-
Amicus Therapeutics (FOLD) PT Raised to $31 at Cowen; 'Very Encouraged by Strong Galafold ex-US Launch'
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018
-
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
-
Amicus Therapeutics (FOLD) Prices 19.35M Share Common Offering at $15.50/Sh
-
Amicus Therapeutics Prices Underwritten Offering of Common Stock
-
Amicus Therapeutics (FOLD) to Offer $250M in Stock
-
Amicus Therapeutics Announces Public Offering of Common Stock
-
Amicus Therapeutics (FOLD) PT Raised to $22 at Cowen, Street High, 'Strong Momentum For Galafold Launch, More Ph2 Pompe Data Up Next'
-
Amicus Therapeutics (FOLD) PT Raised to $18 at Cowen Despite Ph3 ESSENCE Miss
-
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
Amicus Therapeutics (FOLD) Prices 18.37M Share Underwritten Common Offering at $12.25/Sh
-
Amicus Therapeutics Prices Underwritten Offering of Common Stock
-
Amicus Therapeutics (FOLD) Commences $225M Common Stock Offering
-
Amicus Therapeutics Announces Public Offering of Common Stock
-
Amicus Therapeutics to Present at Upcoming Investor Conferences
-
Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
-
Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
-
Amicus Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
-
Amicus Therapeutics (FOLD) PT Cut to $13 at Cowen on Galafold NDA Delay
-
Notable Analyst Rating Changes 9/16: (CST) (YNDX) (ORCL) Upgraded; (HST) (FOLD) (MRK) Downgraded
-
Cowen Raises Price Target on Amicus Therapeutics (FOLD) Following Announced Deal for Scioderm
-
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
-
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
-
Amicus Therapeutics (FOLD) Has a Number of Key Catalysts Upcoming, Cowen Notes
-
Amicus Therapeutics (FOLD) Prices 16.98M Common Secondary Offering at $13.25/Share
-
Amicus Therapeutics Prices Underwritten Offering of Common Stock
-
Amicus Therapeutics Prices Underwritten Offering of Common Stock
-
Amicus Therapeutics (FOLD) Announces $150M Common Stock Offering
-
Amicus Therapeutics Announces Public Offering of Common Stock
-
Amicus Therapeutics Announces Public Offering of Common Stock
-
Amicus Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference
-
Amicus Therapeutics (FOLD) Closes 13.85M Common Offering
-
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
-
Amicus Therapeutics (FOLD) Prices 13.85M Common Secondary at $6.50/Share
-
Amicus Therapeutics (FOLD) Reports $75M Stock Offering
-
Streetinsider.com's Hot Lunchtime Reads 8/20: (IRF) (HPQ) (GTAT) (FL) (DDD)
-
Amicus Therapeutics (FOLD) PT Raised to $14 at Cowen on '012 Data
-
Notable Analyst Rating Changes 07/01: (NFLX) (FOLD) (NBR) Upgraded; (GS) (MNKD) (URBN) Downgraded
-
Morning Movers 07/18: (SUPN) (GALE) (AIR) (APH) Higher; (ROVI) (WHX) (HHS) Lower
-
Amicus Therapeutics (FOLD) Prices 10M Offering at $5.70/Share
-
Amicus Therapeutics (FOLD) Announces Proposed Common Stock Offering
-
Cowen Starts Amicus Therapeutics (FOLD) at Outperform
